Free Kindle Form

Article

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Related Content
First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

Ariana Pelosci
August 21st 2025
Article
Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 21st 2025
Podcast
The safety profile of carfilzomib, lenalidomide, and dexamethasone was tolerable in fit patients with newly diagnosed multiple myeloma.

Weekly Carfilzomib Combination Shows MRD Negativity in Multiple Myeloma

Roman Fabbricatore
August 21st 2025
Article
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 21st 2025
Podcast
Induction chemotherapy may allow investigators to biologically select patients with a favorable prognosis who benefit most from chemoradiotherapy.

Chemoradiation May Convert Unresectable Pancreatic Cancers for Resection

Russ Conroy
August 21st 2025
Article
The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.

Low Dose-Averaged LET Exhibits Poor Local Control in Pancreatic Cancer

Roman Fabbricatore
August 21st 2025
Article